Lemaitre Vascular Inc

Health Care
Medical/Dental Instruments
www.lemaitre.com

Earnings Score
Moat Score

Market Cap $2.27B
PE 55
Debt $NaN
Cash $21.00M
EV $NaN
FCF $33.49M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$41.32M
EBIT	$54.17M
ROE	12%
ROA	14%
FCF	$33.49M
Equity	$331.07M
Growth Stability	94%
PE	54.9
PEG	3.86
PB	6.85
P/FCF	67.73
P/S	10.65
Price/Cash	0.01
Net Margins	20%
Gross Margins	68%
Op. Margins	25%
Earnings CAGR	14%
Sales Growth YoY	16%
Sales Growth QoQ	-2%
Sales CAGR	12%
FCF CAGR	13%
Equity CAGR	19%
Earnings Stability	0.76
Earnings Growth YoY	49%
Earnings Growth QoQ	-6%

Earnings CAGR 5Y	14%
Sales CAGR 5Y	14%
FCF CAGR 5Y	12%
Equity CAGR 5Y	20%
Earnings CAGR 3Y	13%
Sales CAGR 3Y	13%
FCF CAGR 3Y	6%
Equity CAGR 3Y	10%
Market Cap	$2.27B
Revenue	$213.03M
Dividend Yield	1%
Payout Ratio	34%
Assets	$377.03M
Cash	$21.00M
Shares Outstanding	22.43M
Earnings Score	92%
Moat Score	94%
Working Capital	197.77M
Current Ratio	7.74
Gross Profit	$145.58M
Shares Growth 3y	1%
Equity Growth QoQ	4%
Equity Growth YoY	15%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

SEC Filings

Direct access to Lemaitre Vascular Inc (LMAT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Lemaitre Vascular Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Lemaitre Vascular Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 14%

Stability 76%

loading chart...

Lemaitre Vascular Inc Discounted Cash Flow

Fully customizable DCF calculator online for Lemaitre Vascular Inc.

Years

Calculation mode

= $810M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$33M	$38M	$43M	$48M	$54M	$61M	$69M	$77M	$87M	$98M	$111M	$1.1B
DCF		$34M	$35M	$36M	$37M	$38M	$39M	$40M	$41M	$42M	$43M	$427M
Value	$810M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	6%	10%	12%	17%	22%	15%	16%	17%	13%	16%	20%
ROA	-	13%	16%	17%	19%	12%	11%	12%	9%	11%	14%
ROE	-	10%	12%	16%	18%	12%	12%	11%	8%	10%	12%

Good Net Margins (20.02%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	0	1.12	0	-	-	-
Debt over Equity	-	-	-	-	-	0	0.21	0	-	-	-
Growth Stability	-	-	-	100%	100%	100%	100%	100%	94%	100%	94%

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (94%)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	10%	14%	13%	5%	11%	10%	19%	5%	20%	14%
Earnings YoY growth	-	98%	37%	62%	34%	-22%	18%	27%	-23%	46%	14%
Equity YoY growth	-	14%	12%	25%	19%	14%	16%	47%	6%	11%	20%
FCF YoY growth	-	111%	53%	17%	0%	-37%	205%	-5%	-27%	33%	12%